Cutaneous T-cell lymphoma

被引:18
作者
Kotz, EA
Anderson, D
Thierst, BH
机构
[1] Med Univ S Carolina, Dept Dermatol, Charleston, SC 29425 USA
[2] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA
关键词
cutaneous T cell lymphoma; mycosis fungoides; sezary syndrome;
D O I
10.1046/j.1468-3083.2003.00635.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Cutaneous T-cell lymphoma (CTCL) is a neoplasm of helper T cells whose first manifestations usually appear in the skin. The various forms of CTCL are distinguished by both clinical features and histopathology. Early on, the diagnosis may be difficult to establish because of its numerous, and often non-specific, clinical presentations. Further, the pathological findings of early lesions may lack the diagnostic features observed in well-developed or advanced disease. The diagnosis of CTCL must be considered in any patient with a chronic, therapy-resistant condition of the skin. In patients with non-specific histological findings, a high index of suspicion and multiple biopsies may eventually lead to a diagnosis of CTCL. Once the diagnosis of CTCL is established, accurate staging is essential both for its effect on treatment decisions and for its prognostic value. In general, CTCL is a chronic, slowly progressive disease with a long evolution. The development of tumours is a poor prognostic sign, as is erythroderma. The Sezary syndrome is a distinct form of erythrodermic CTCL that is characterized by exfoliative erythroderma, lymphadenopathy, lymphocytosis, intense pruritus, and circulating large, abnormal lymphocytes (Sezary cells). When death does occur, it is most often due to septicemia. Treatment of CTCL must be tailored to the individual patient. The most commonly employed treatment options are photochemotherapy and topical chemotherapy.
引用
收藏
页码:131 / 137
页数:7
相关论文
共 28 条
  • [1] BUNN PA, 1979, CANCER TREAT REP, V63, P725
  • [2] MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA
    CARNEY, DN
    BUNN, PA
    [J]. JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, 1980, 6 (05): : 369 - 377
  • [3] COLBY TV, 1981, CANCER, V47, P351, DOI 10.1002/1097-0142(19810115)47:2<351::AID-CNCR2820470224>3.0.CO
  • [4] 2-4
  • [5] EPSTEIN EH, 1972, MEDICINE, V15, P61
  • [6] FISCHMANN AB, 1979, CANCER TREAT REP, V63, P591
  • [7] HEALD PW, 1999, FITZPATRICKS DERMATO, P1242
  • [8] Clinical stage IA (limited patch and plaque) mycosis fungoides - A long-term outcome analysis
    Kim, YH
    Jensen, RA
    Watanabe, GL
    Varghese, A
    Hoppe, RT
    [J]. ARCHIVES OF DERMATOLOGY, 1996, 132 (11) : 1309 - 1313
  • [9] Kim YH, 1999, SEMIN ONCOL, V26, P276
  • [10] Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides
    Kim, YH
    Chow, S
    Varghese, A
    Hoppe, RT
    [J]. ARCHIVES OF DERMATOLOGY, 1999, 135 (01) : 26 - 32